Latest Research Breakthroughs at ASH 2025: How We’re Accelerating the Search for a Cure
Every December, over 30,000 haematology experts from around the world gather for the American Society of Haematology (ASH) conference, where groundbreaking research is shared and the future of lymphoma treatment takes shape. In December 2025, the FLF team was at ASH in Orlando, USA on a clear mission: to find out the latest breakthroughs, represent you and drive progress toward a cure for follicular lymphoma.
2025 Impact Round-Up: Turning Belief into Progress for Follicular Lymphoma
In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as Global CEO, Emma France reflects on the turning points that pushed progress from possibility into action and shares how the FL community is shaping a future where cures become achievable.
Updates from the 2025 American Society of Hematology (ASH) Annual Meeting
The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research.
Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
Unlock the Cure Gala 2025 Raises Funds for Vital Research
The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with follicular lymphoma.
Highlights from our satellite symposium “Charting our Progress Towards a Cure”
At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.
Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.
The Power of Seed Funding: Accelerating Research in Follicular Lymphoma
One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding of the world-renowned Dana-Farber Cancer Institute.
FLF shines a spotlight on follicular lymphoma at 18-ICML
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
Driving Breakthroughs in Follicular Lymphoma Research
At the Follicular Lymphoma Foundation (FLF), we’re funding bold, high-impact research to transform what it means to live with follicular lymphoma (FL). Guided by ongoing input from patients, we’re focused on accelerating progress toward cure.